Radiology solutions company Imaging Endpoints launches new research subsidiary

Imaging Endpoints, a clinical trial-focused radiology company, has launched a new research subsidiary, the firm announced Wednesday.

Scottsdale, Arizona-based Imaging Endpoints said the new wholly-owned Research Endpoints will manage the growing demand for its exploratory imaging research and biomarker discovery business.

With more than 100 physicians across the U.S., including 40 in-house radiologists, the firm supports imaging research with services that include textural analysis, radiomics and artificial intelligence.

Imaging Endpoints and its new sister company will both share the same executive leadership team and scientific advisory board. The latter includes renowned Johns Hopkins Radiology Professor Elliot K. Fishman, MD, who was appointed back in January.

"The formation of Research Endpoints is yet another example of our desire to ensure that our sponsors, partners, investigators, and patients continue to benefit from our industry-leading science and analytics,” Chief Medical Officer Ron Korn, MD, PhD, said in a statement.

Imaging Endpoints is an affiliate of Scottsdale-based HonorHealth, which operates some 70 primary and specialty care clinics along with six hospitals, according to its website. IE is also affiliated with Southwest Medical Imaging, one of the largest private radiology groups in the U.S.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.